Vivos Therapeutics, Inc. Deferred Revenue Recognized
Vivos Therapeutics, Inc. (VVOS) reported Deferred Revenue Recognized of -$511.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-14
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was -$162.00K.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was -$274.00K.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was -$298.00K.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was -$422.00K.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was -$1.48M.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was -$3.55M.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was -$4.34M.
- Vivos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was -$5.93M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$511.00K 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | -$162.00K 10-Q · filed 2026-05-20 | ||||
| 2025-12-31 | -$1.48M 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | -$274.00K 10-Q · filed 2025-11-19 | ||||
| 2025-06-30 | -$298.00K 10-Q · filed 2025-11-19 | -$720.00K 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$422.00K 10-Q · filed 2026-05-20 | ||||
| 2024-12-31 | -$3.55M 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | -$931.00K 10-Q · filed 2025-11-19 | ||||
| 2024-06-30 | -$1.20M 10-Q · filed 2025-11-19 | ||||
| 2024-03-31 | -$962.00K 10-Q · filed 2025-11-19 | ||||
| 2023-12-31 | -$4.34M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$1.06M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$1.07M 10-Q · filed 2024-11-14 | ||||
| 2023-03-31 | -$1.40M 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | -$5.93M 10-K/A · filed 2024-07-30 | ||||
| 2022-09-30 | -$1.77M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | -$1.32M 10-Q · filed 2023-11-14 | ||||
| 2022-03-31 | -$1.42M 10-Q · filed 2023-11-14 | -$1.24M 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | -$8.52M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | -$2.33M 10-Q · filed 2022-12-20 | -$2.33M 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | -$2.35M 10-Q · filed 2022-12-20 | -$2.35M 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | -$1.75M 10-Q · filed 2022-12-20 | -$1.75M 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | -$7.54M 10-K · filed 2022-03-31 | -$7.54M 10-K · filed 2021-03-25 | |||
| 2020-09-30 | -$1.74M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | -$2.51M 10-Q · filed 2021-11-15 | ||||
| 2020-03-31 | -$1.54M 10-Q · filed 2021-11-15 | ||||
| 2019-12-31 | -$6.74M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |